admin – Page 4098 – Get News Story

Idiopathic Membranous Nephropathy Market, 2034 | Bristol Myers Squibb Company, Merck and Co Inc., Mylan Pharmaceutical ltd., Novartis AG, Pfizer Inc., Roche, Aspen Global Inc., Astell

“Idiopathic Membranous Nephropathy Market 2034”

The Idiopathic Membranous Nephropathy market growth is driven by factors like increase in the prevalence of Idiopathic Membranous Nephropathy, investments in research and development, entry of emerging therapies during the study period 2020-2034.

The Idiopathic Membranous Nephropathy market report also offers comprehensive insights into the Idiopathic Membranous Nephropathy market size, share, Idiopathic Membranous Nephropathy epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Idiopathic Membranous Nephropathy market size growth forward.

Some of the key highlights from the Idiopathic Membranous Nephropathy Market Insights Report:

Several key pharmaceutical companies, including Bristol Myers Squibb Company, Merck and Co Inc., Mylan Pharmaceutical ltd., Novartis AG, Pfizer Inc., Roche, Aspen Global Inc., Astellas Pharma Inc., Baxter Healthcare Corporation, Sigma Aldrich Corporation, and others, are developing novel products to improve the Idiopathic Membranous Nephropathy treatment outlook.
The Idiopathic Membranous Nephropathy (IMN) market in the 7MM is projected to reach approximately USD 1,000 million by 2034. In 2023, the United States held the largest market share, generating around USD 88 million, surpassing EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.
IMN is a major glomerular disease characterized by excessive protein loss in the urine (nephrotic syndrome) and is primarily autoimmune in nature. Currently, there are no approved treatments specifically for IMN, with management focused on supportive care. However, the market is expected to grow due to improved uptake of existing drugs, upcoming therapy launches, and increased awareness.
In 2023, the estimated total prevalent IMN population in the 7MM was approximately 71,000 cases. The US accounted for about 40% of these cases, while EU4 and the UK collectively made up around 35%, and Japan contributed approximately 25%, making it the second-largest region after the US.
Several emerging therapies are in development, including TNT119, ALPN-303, MOR202, SNP-ACTH (1-39) Gel, and GAZYVA. Notably, in October 2023, the FDA granted Breakthrough Therapy designation (BTD) to felzartamab for primary membranous nephropathy. Additionally, in June 2023, the FDA awarded orphan drug designation (ODD) to SNP-ACTH (1-39) gel for treating primary membranous nephropathy.
In July 2024, Biogen finalized its acquisition of Human Immunology Biosciences (HI-Bio). Earlier, in June 2022, HI-Bio had entered an agreement with MorphoSys AG to develop and commercialize the anti-CD38 antibody felzartamab.
As per DelveInsight analysis, the Idiopathic Membranous Nephropathy market is anticipated to witness growth at a considerable CAGR

Strategise your business goals by understanding market dynamics @ Idiopathic Membranous Nephropathy Market Landscape

Idiopathic Membranous Nephropathy Overview

Idiopathic Membranous Nephropathy is a common glomerular disease closely linked to nephrotic syndrome. It occurs when the immune system mistakenly attacks the glomeruli, resulting in excessive protein loss in urine (proteinuria), swelling (edema), and, in some cases, progression to kidney failure. The term “idiopathic” indicates that no clear underlying cause has been identified, though the condition may also develop due to autoimmune disorders or infections. This disease primarily affects adults, particularly middle-aged men, and manifests through symptoms such as foamy urine, leg and abdominal swelling, and weight gain caused by fluid retention.

Diagnosis involves a combination of clinical evaluation and laboratory tests. Urine analysis detects proteinuria, often exceeding 3.5 g/day, while blood tests assess kidney function, low albumin levels (hypoalbuminemia), and lipid imbalances (dyslipidemia), which are typical of nephrotic syndrome. A kidney biopsy remains the gold standard for diagnosis, revealing immune complex deposits along the glomerular capillary walls. Additionally, serological testing for antibodies like anti-PLA2R helps distinguish primary Idiopathic Membranous Nephropathy from secondary forms, aiding in precise treatment decisions.

Do you know the treatment paradigms for different countries? Download our Idiopathic Membranous Nephropathy Market Sample Report

Idiopathic Membranous Nephropathy Epidemiology Insights

In 2023, the United States represented approximately 40% of the total prevalent cases of Idiopathic Membranous Nephropathy across the 7MM.
Meanwhile, Japan’s prevalence data indicates a relatively steady trend projected over the forecast period from 2024 to 2034.

Idiopathic Membranous Nephropathy Epidemiology Segmentation

DelveInsight’s Idiopathic Membranous Nephropathy market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Idiopathic Membranous Nephropathy historical patient pools and forecasted Idiopathic Membranous Nephropathy patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Idiopathic Membranous Nephropathy Market report proffers epidemiological analysis for the study period 2020-34 in the 7MM segmented into:

Idiopathic Membranous Nephropathy Prevalence
Age-Specific Idiopathic Membranous Nephropathy Prevalence
Gender-Specific Idiopathic Membranous Nephropathy Prevalence
Diagnosed and Treatable Cases of Idiopathic Membranous Nephropathy

Visit for more @ Idiopathic Membranous Nephropathy Epidemiological Insights

Idiopathic Membranous Nephropathy Market Outlook

Key companies, including Hoffmann-La Roche, HI-Bio, Cerium Pharmaceuticals, BeiGene, and others, are advancing their lead candidates through various stages of clinical development. Their goal is to explore these products as treatments for Idiopathic Membranous Nephropathy.

In the 7MM, MOR202 (felzartamab) is projected to achieve the highest market revenue, reaching approximately USD 500 million by 2034. Among the EU4 and the UK, Germany had the largest market share, with an estimated value of around USD 10 million in 2023. Japan’s market is anticipated to grow to approximately USD 70 million by 2034. In 2023, Rituximab generated roughly USD 50 million in revenue across the 7MM.

Idiopathic Membranous Nephropathy Emerging Drugs

GAZYVA (obinutuzumab): Hoffmann-La Roche
SNP-ACTH (1-39) Gel: Cerium Pharmaceuticals

Idiopathic Membranous Nephropathy Key Companies

Bristol Myers Squibb Company, Merck and Co Inc., Mylan Pharmaceutical ltd., Novartis AG, Pfizer Inc., Roche, Aspen Global Inc., Astellas Pharma Inc., Baxter Healthcare Corporation, Sigma Aldrich Corporation, and others

For more information, visit Idiopathic Membranous Nephropathy Market Analysis, Patient Pool, and Emerging Therapies

Scope of the Idiopathic Membranous Nephropathy Market Report:

11 Years Forecast
7MM Coverage
Descriptive overview of Idiopathic Membranous Nephropathy, causes, signs and symptoms, diagnosis, treatment
Comprehensive insight into Idiopathic Membranous Nephropathy epidemiology in the 7MM
Idiopathic Membranous Nephropathy marketed and emerging therapies
Idiopathic Membranous Nephropathy companies
Idiopathic Membranous Nephropathy market drivers and barriers

Table of Contents:

1 Idiopathic Membranous Nephropathy Market Key Comprehensive Insights

2 Idiopathic Membranous Nephropathy Market Report Introduction

3 Competitive Intelligence Analysis for Idiopathic Membranous Nephropathy

4 Idiopathic Membranous Nephropathy Market Analysis Overview at a Glance

5 Executive Summary of Idiopathic Membranous Nephropathy

6 Idiopathic Membranous Nephropathy Epidemiology and Market Methodology

7 Idiopathic Membranous Nephropathy Epidemiology and Patient Population

8 Idiopathic Membranous Nephropathy Patient Journey

9 Idiopathic Membranous Nephropathy Treatment Algorithm, Idiopathic Membranous Nephropathy Current Treatment, and Medical Practices

10 Key Endpoints in Idiopathic Membranous Nephropathy Clinical Trials

11 Idiopathic Membranous Nephropathy Marketed Therapies

12 Idiopathic Membranous Nephropathy Emerging Therapies

13 Idiopathic Membranous Nephropathy: 7 Major Market Analysis

14 Attribute analysis

15 Access and Reimbursement Overview of Idiopathic Membranous Nephropathy

16 Idiopathic Membranous Nephropathy Market Key Opinion Leaders Reviews

18 Idiopathic Membranous Nephropathy Market Drivers

19 Idiopathic Membranous Nephropathy Market Barriers

20 SWOT Analysis

21 Disclaimer

22 DelveInsight Capabilities

23 About DelveInsight

Related Reports:

Idiopathic Membranous Nephropathy Epidemiology 2034

DelveInsight’s “Idiopathic Membranous Nephropathy – Epidemiology Forecast to 2034” report delivers an in-depth understanding of the disease, historical and forecasted Idiopathic Membranous Nephropathy epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Idiopathic Membranous Nephropathy Pipeline 2024

“Idiopathic Membranous Nephropathy Pipeline Insights, 2024” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Idiopathic Membranous Nephropathy market. A detailed picture of the Idiopathic Membranous Nephropathy pipeline landscape is provided, which includes the disease overview and Idiopathic Membranous Nephropathy treatment guidelines.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Idiopathic Membranous Nephropathy Market, 2034 | Bristol Myers Squibb Company, Merck and Co Inc., Mylan Pharmaceutical ltd., Novartis AG, Pfizer Inc., Roche, Aspen Global Inc., Astell

Leading the Way in Continuous Improvement Procedure: Compliance Expert Eases Procedure with Step-by-Step ISO Guidelines

Continuous improvement is the key to achieving success in any organization, and Endeavour Technical Limited is an essential tool to implement this procedure.

The International Organisation for Standardization (ISO) provides a framework for ensuring consistent and reliable processes to help businesses improve their operational efficiency. A key component of ISO standards is the focus on continuous improvement, which helps companies stay competitive and responsive to changing markets.

Richard Keen, Compliance Director of Endeavour Technical Limited, offers insights on how organizations can achieve their goals through a continuous improvement procedure. With extensive experience working with a range of organizations of all sizes across a variety of industries, Mr. Keen’s expertise in ISO procedure enables him to guide organizations through the process of continuous improvement, identifying areas for improvement, implementing changes, and measuring the impact of those changes.

The purpose of the framework for continuous improvement is to enable businesses to continually review and refine processes, ensuring objectives, deliverables, and customer service standards are met. By implementing it, businesses can ensure they stay up-to-date with changing market conditions and customer expectations.

A one-size-fits-all solution simply does not exist, but Endeavour Technical Limited’s guidelines provide a step-by-step guide to help the ISO project manager develop a continuous improvement plan tailored to the organization. Doing so ensures that the business is working towards continuous improvement and is committed to providing quality products and services to its customers.

As such, Endeavour Technical Limited’s approach is based on a thorough understanding of ISO procedure and a focus on collaboration between the implementing company and its customers. The checklist helps the organization to identify areas where it excels and areas where improvement is needed. The checklist provides a structured approach to implementing the ISO Continuous Improvement Procedure, making the process more efficient and effective.

For more information, visit https://www.iso-9001-checklist.co.uk/10.3-continual-improvement.htm

It is crucial that the project drivers invest the time to understand the organization’s strengths and weaknesses and specific requirements to achieve the decided outcome. Many organisations have experienced significant improvements in their operations. There are countless examples of manufacturing companies struggling with a high level of defects before implementing ISO and recording a 50% reduction in defect rate after its ISO certification.

The ISO Continuous Improvement Procedure is an ongoing process. The organization needs to continually review and improve its processes to ensure that it is meeting the standard guidelines. The Endeavour Technical Limited helps the organization identify areas where it can improve its processes and provides the matrix to implement the improvements.

The ISO Continuous Improvement Procedure is not just about meeting the standard requirements. It is about providing quality products and services to customers. Endeavour Technical Limited helps the business to focus on customer satisfaction and to ensure that its products and services meet the needs of its customers.

Overall, continuous improvement will enable businesses to achieve real, measurable improvements in their operations. Organizations can ensure they stay competitive and responsive to changing market conditions while delivering value to their customers.

Endeavour Technical Limited’s templates and guidelines are essential for any organization intending to successfully implement the ISO Continuous Improvement Procedure. They play a crucial role in ensuring that any organization’s ISO project managers will be effectively guided to meet the standard guidelines of ISO 9001.

About the Company:

Endeavour Technical Limited is an ISO company based in London, UK. The company is dedicated to writing and developing ISO templates for customers worldwide. Endeavour Technical Limited is committed to providing high-quality products and services and excellent customer service. ISO-9001-Checklist.co.uk is a leading provider of quality management resources, including checklists, templates, and guides for ISO 9001 compliance.

Media Contact
Company Name: Endeavour Technical Limited
Contact Person: Richard Keen
Email: Send Email
Phone: 0845 054 2886
Address:71–75 Shelton Street, Covent Garden
City: London WC2H 9JQ
Country: United Kingdom
Website: https://www.iso-9001-checklist.co.uk/

Monjur and MSPAlliance Announce Strategic Partnership to Improve Cybersecurity and Compliance for MSPs

Southlake, Texas – February 18, 2025 – Monjur, renowned for its innovative contract solutions for managed service providers (MSPs), has joined forces with MSPAlliance, the world’s largest international cloud and managed services association. This strategic partnership, founded on the extensive expertise of both Monjur and MSPAlliance, will see the two entities promote and market each other’s solutions. They will also integrate Monjur’s expertise in customer contracting with the MSPAlliance Cyber Verify certification program.

With Monjur’s legal technology, Cyber Verify can help MSPs apply a holistic approach to proving trust, accountability, and compliance with industry standards. The partnership underscores the unwavering commitment of both Monjur and MSPAlliance to elevating cybersecurity and compliance levels within the MSP industry, demonstrating a profound understanding of the unique challenges that MSPs face and providing reassurance to the audience.

“Monjur’s partnership with MSPAlliance is a continuation of the strong, two-decade-long relationship with MSPAlliance,” said Rob Scott, CEO at Monjur. “Through our collaboration, we provide MSPs with the much-needed legal protection and the cybersecurity capability required to grow their businesses securely.”

Cyber Verify is an MSP compliance program purpose-built for MSPs, based on an MSP standard (the Unified Certification Standard for Cloud & Managed Service Providers), and capable of unleashing powerful MSP Compliance as a Service, vCISO, and vCIO services. Through this partnership, Monjur’s customers can obtain the CyberVerify program directly from the company, enhancing their cybersecurity position and providing a competitive edge in the market.

“Monjur possesses a strong grasp of MSP legal agreements and risk mitigation, making them a great fit for our Cyber Verify certification,” said Charles Weaver, CEO of MSPAlliance. “With this partnership, we can offer MSPs legal and cybersecurity audits to help them meet industry standards and build client trust.”

This collaboration will help MSPs work more effectively and with robust security as the digital world becomes increasingly complex. Visit Monjur’s website to learn more about them and their legal services. Visit MSPAlliance’s website to learn more about Cyber Verify. Email Thomas Mustac from OtterPR at thomas.mustac@otterpr.com for media inquiries or further information.

About Monjur

Monjur is redefining how businesses consume legal services by offering simple, scalable solutions tailored to the unique challenges of today’s recurring revenue-based industries. Unlike traditional legal services, Monjur provides predictable, subscription-based pricing and on-demand access to legal expertise, eliminating the uncertainty of hourly billing and costly retainers.

About MSPAlliance

MSPAlliance® is a global industry association and accrediting body for the Cyber Security, Cloud Computing, and Managed Services Provider (MSP) industry. Established in 2000, MSPAlliance has been dedicated to helping MSPs become better service providers. Collaborating with corporate members worldwide, MSPAlliance works towards setting standards, policies, and best practices, benefiting its members and governments alike.

For more information, visit www.mspalliance.com

Media Contact
Company Name: Otter Public Relations
Contact Person: Thomas Mustac
Email: Send Email
Address:136 4th St N Ste 201
City: ORLANDO
State: FL
Country: United States
Website: www.otterpr.com

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Monjur and MSPAlliance Announce Strategic Partnership to Improve Cybersecurity and Compliance for MSPs

Epidermolysis Bullosa Market Expected to rise, 2034 | Amryt Pharma, Abeona Therapeutics, Castle Creek Pharmaceuticals, RegeneRx, Krystal Biotech, Fibrocell Technologies, RHEACELL GmbH, Holostem Terapi

“Epidermolysis Bullosa Market 2034”

The Epidermolysis Bullosa market growth is driven by factors like increase in the prevalence of Epidermolysis Bullosa, investments in research and development, entry of emerging therapies during the study period 2020-2034.

The Epidermolysis Bullosa market report also offers comprehensive insights into the Epidermolysis Bullosa market size, share, Epidermolysis Bullosa epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Epidermolysis Bullosa market size growth forward.

Some of the key highlights from the Epidermolysis Bullosa Market Insights Report:

Several key pharmaceutical companies, including Amryt Pharma, Abeona Therapeutics, Castle Creek Pharmaceuticals, RegeneRx, Krystal Biotech, Fibrocell Technologies, RHEACELL GmbH, Holostem Terapie Avanzate, StemRim, Shionogi, Phoenix Tissue Repair (BridgeBio Pharma, Inc), Menlo Therapeutics, JCR Pharmaceuticals, Amicus Therapeutics, and others, are developing novel products to improve the Epidermolysis Bullosa treatment outlook.
In September 2024, a small real-world study showed that Janus kinase (JAK) inhibitors, such as upadacitinib and baricitinib, were more effective than dupilumab in reducing itching and skin lesions in individuals with epidermolysis bullosa pruriginosa (EBP). Among five patients treated with dupilumab, only two experienced a 50% reduction in itching, and none achieved complete relief. In contrast, all five patients treated with JAK inhibitors reported full relief from itching.
In December 2023, the FDA approved the use of Filsuvez, a topical gel containing birch triterpenes from Chiesi Global Rare Diseases, for treating partial thickness wounds in patients with junctional and dystrophic epidermolysis bullosa (EB). This approval marks Filsuvez as the only FDA-approved treatment for junctional EB. The decision was based on results from the phase 3 EASE trial, which involved 223 participants across 58 sites in 28 countries, including a three-month randomized controlled phase and a 24-month open-label phase.
In 2023, the Epidermolysis Bullosa (EB) market was largest in the US, with a market size of approximately USD 1,300 million, and it is expected to grow further by 2034. Epidermolysis Bullosa simplex (EBS) is the least severe form, with many individuals experiencing improvements as they age, while recessive dystrophic Epidermolysis Bullosa is considered the most severe type. In 2023, over 30% of EB cases were attributed to dystrophic EB, while only 5% were linked to junctional EB.
Currently, there are limited effective treatments for EB, and management primarily focuses on supportive care, including wound care, pain and itch management, infection control, nutritional support, and treating complications. Stem cell-based therapies, particularly ABCB5+ mesenchymal stromal cells (MSCs), are gaining attention due to their immunomodulatory and anti-inflammatory properties, showing promise for treating chronic inflammatory conditions like EB.
Japan is leading in cell therapy development, having approved the first cell therapy for EB, JACE (human epidermal cell sheet), in December 2018. There is also significant competition in gene therapy development for EB, with Krystal leading by securing FDA approval for VYJUVEK, effective for both recessive and dominant forms of the disease. Abeona’s EB-101, a similar gene therapy, also shows promising results. Although Krystal is a year ahead in development, both therapies are vying for market share.
Despite these advancements, there remains a significant unmet need for EB therapies, highlighting the importance of continued research and development to improve treatment options and the quality of life for EB patients globally.
As per DelveInsight analysis, the Epidermolysis Bullosa market is anticipated to witness growth at a considerable CAGR

Strategise your business goals by understanding market dynamics @ Epidermolysis Bullosa Market Landscape

Epidermolysis Bullosa Overview

Epidermolysis Bullosa (EB) is a genetic skin disorder marked by fragile skin that blisters easily due to minimal friction or trauma. It is caused by mutations in genes that affect skin proteins essential for structural integrity. The severity of EB varies, from mild cases to life-threatening forms, depending on the subtype. The patient journey typically begins with symptoms like frequent blistering and slow wound healing, prompting caregivers to seek medical attention. Diagnosis is confirmed through skin biopsy and genetic testing to classify the subtype. Following diagnosis, a multidisciplinary team, including dermatologists, wound care specialists, nutritionists, and physiotherapists, develops a treatment plan. Emotional support is also important to help patients cope with the condition. Long-term care and regular follow-ups are essential to monitor skin health and prevent complications. Early diagnosis plays a key role in improving the patient’s quality of life.

Do you know the treatment paradigms for different countries? Download our Epidermolysis Bullosa Market Sample Report

Epidermolysis Bullosa Epidemiology Insights

In 2023, the United States had the highest prevalence of Epidermolysis Bullosa, making up approximately 65% of the total cases across the 7MM. Meanwhile, the EU4 countries and the UK accounted for around 30%, and Japan represented about 5% of the total prevalence.
Within the EU4 and UK regions, the United Kingdom had the highest number of cases, followed by Germany, while Spain had the fewest cases in 2023.

Epidermolysis Bullosa Epidemiology Segmentation

DelveInsight’s Epidermolysis Bullosa market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Epidermolysis Bullosa historical patient pools and forecasted Epidermolysis Bullosa patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Epidermolysis Bullosa Market report proffers epidemiological analysis for the study period 2020-34 in the 7MM segmented into:

Epidermolysis Bullosa Prevalence
Age-Specific Epidermolysis Bullosa Prevalence
Gender-Specific Epidermolysis Bullosa Prevalence
Diagnosed and Treatable Cases of Epidermolysis Bullosa

Visit for more @ Epidermolysis Bullosa Epidemiological Insights

Epidermolysis Bullosa Market Insights

Ongoing research into Epidermolysis Bullosa (EB) treatments includes various approaches like gene therapies, cell-based therapies, recombinant protein therapies, and small molecule treatments. Gene therapies, especially VYJUVEK, the first FDA-approved topical gene therapy, are progressing significantly. Other contenders, including Abeona and Castle Creek Biosciences, also aim to introduce COL7A1 into the body.

VYJUVEK uses herpes simplex virus type 1 (HSV-1) as a gene therapy vector, which doesn’t integrate into the host’s genome, reducing the risk of cancer. JACE, approved in 2018, was the first cell therapy approved for EB. Additionally, stem cell therapies, particularly those using ABCB5+ mesenchymal stromal cells, show promise due to their immune-modulatory properties, aiding chronic wound healing. Other cell-based treatments, such as ISN001 from Ishin Pharma and ALLO-RV-LAMB3-transduced epidermal stem cells from Holostem Terapie Avanzate, are also in development.

Epidermolysis Bullosa Marketed Drugs

VYJUVEK (beremagene geperpavec): Krystal Biotech
FILSUVEZ (oleogel-S10): Chiesi Farmaceutici

Epidermolysis Bullosa Emerging Drugs

EB-101: Abeona Therapeutics
D-Fi (dabocemagene autoficel): Castle Creek Biosciences

Epidermolysis Bullosa Key Companies

Amryt Pharma, Abeona Therapeutics, Castle Creek Pharmaceuticals, RegeneRx, Krystal Biotech, Fibrocell Technologies, RHEACELL GmbH, Holostem Terapie Avanzate, StemRim, Shionogi, Phoenix Tissue Repair (BridgeBio Pharma, Inc), Menlo Therapeutics, JCR Pharmaceuticals, Amicus Therapeutics, and others

For more information, visit Epidermolysis Bullosa Market Analysis, Patient Pool, and Emerging Therapies

Scope of the Epidermolysis Bullosa Market Report:

11 Years Forecast
7MM Coverage
Descriptive overview of Epidermolysis Bullosa, causes, signs and symptoms, diagnosis, treatment
Comprehensive insight into Epidermolysis Bullosa epidemiology in the 7MM
Epidermolysis Bullosa marketed and emerging therapies
Epidermolysis Bullosa companies
Epidermolysis Bullosa market drivers and barriers

Table of Contents:

1 Epidermolysis Bullosa Market Key Comprehensive Insights

2 Epidermolysis Bullosa Market Report Introduction

3 Competitive Intelligence Analysis for Epidermolysis Bullosa

4 Epidermolysis Bullosa Market Analysis Overview at a Glance

5 Executive Summary of Epidermolysis Bullosa

6 Epidermolysis Bullosa Epidemiology and Market Methodology

7 Epidermolysis Bullosa Epidemiology and Patient Population

8 Epidermolysis Bullosa Patient Journey

9 Epidermolysis Bullosa Treatment Algorithm, Epidermolysis Bullosa Current Treatment, and Medical Practices

10 Key Endpoints in Epidermolysis Bullosa Clinical Trials

11 Epidermolysis Bullosa Marketed Therapies

12 Epidermolysis Bullosa Emerging Therapies

13 Epidermolysis Bullosa: 7 Major Market Analysis

14 Attribute analysis

15 Access and Reimbursement Overview of Epidermolysis Bullosa

16 Epidermolysis Bullosa Market Key Opinion Leaders Reviews

18 Epidermolysis Bullosa Market Drivers

19 Epidermolysis Bullosa Market Barriers

20 SWOT Analysis

21 Disclaimer

22 DelveInsight Capabilities

23 About DelveInsight

Related Reports:

Epidermolysis Bullosa Epidemiology 2034

DelveInsight’s “Epidermolysis Bullosa – Epidemiology Forecast to 2034” report delivers an in-depth understanding of the disease, historical and forecasted Epidermolysis Bullosa epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Epidermolysis Bullosa Pipeline 2024

“Epidermolysis Bullosa Pipeline Insights, 2024” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Epidermolysis Bullosa market. A detailed picture of the Epidermolysis Bullosa pipeline landscape is provided, which includes the disease overview and Epidermolysis Bullosa treatment guidelines.

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Epidermolysis Bullosa Market Expected to rise, 2034 | Amryt Pharma, Abeona Therapeutics, Castle Creek Pharmaceuticals, RegeneRx, Krystal Biotech, Fibrocell Technologies, RHEACELL GmbH, Holostem Terapi

PWC-NY Survey Strives to Raise Awareness About Advantages for Women Working in the Construction Industry

““Today there are only 1.3 million women employed in the construction industry, despite its being ranked as the number one paying industry for women,” explains Regina Rivera, PWC NY Executive Director. “Although progress has been made over the years, PWC NY created this survey of its members in hopes of encouraging more women to choose construction as a career path, by learning from the experiences of those surveyed, and sharing the benefits and advantages they prioritized.””

A recent survey conducted by the New York chapter of Professional Women in Construction (PWC NY) shows that women employed in construction find many benefits to working in the industry and suggests ways to break barriers and increase awareness of opportunities for women.

According to the U.S. Bureau of Labor Statistics, 46.9% of women are employed in the total workforce, but women represent only 10.8% of workers in the male dominated industry of construction. Women are grossly underrepresented, in spite of the fact that it has one of the lowest gender pay gaps with women earning 95% of their male counterparts (compared to an average of 81% gender gap for all industries) and the salary of a female construction manager averaging $97,180 annually. Professional Women in Construction’s New York Chapter (PWC NY) conducted a survey of its members to help determine the reasons for this disparity and to seek suggestions for filling the void of female workers in the industry.

The survey revealed that the greater pay scale and advancement opportunities within the construction industry were the primary reasons for seeking a job in the field, followed by professional development, substantial benefits, and job security.

Some of the highlights that women noted working in the industry include contributing to the development of a building from start to finish; taking pride in a tangible result that required problem-solving and creativity; having the opportunity to grow; and the gratification of being a trailblazer for other women.

To encourage and welcome more women into the industry, the survey respondents suggested holding seminars and job fairs that tailor to skills inherent in women, such as communication, detail focus and organization, as well as highlight the work-life-balance possibilities in the construction field

Construction is a male-dominated industry creating a stereotypical stigma that prevents women from joining the industry. The survey revealed that the main barrier is the lack of awareness of the professional jobs in the field, suggesting that education is key to allowing women to see the limitless opportunities.

Professional Women in Construction is a nonprofit organization that supports and connects women in the fields of architecture, engineering, construction, and related industries. New York is the founding chapter of PWC, established in 1980 by eight women who banded together to support each other in advancing their careers and businesses. PWC offers informative industry programming, exclusive member resources, leadership and networking opportunities, and scholarships and mentorship programs.

Media contact: Liz Ammirato, liz@callprinc.com

Media Contact
Company Name: CATHY CALLEGARI PUBLIC RELATIONS INC
Contact Person: Liz Ammirato
Email: Send Email
Phone: 914-299-3882
Address:159 Madison Avenue, Apt. 5J
City: New York
State: NY
Country: United States
Website: www.callprinc.com

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: PWC-NY Survey Strives to Raise Awareness About Advantages for Women Working in the Construction Industry

Peripheral Neuropathic Pain Market Expected to rise, 2034 | Daiichi Sankyo, Scilex Pharmaceuticals, Azurity Pharmaceuticals, Lexicon Pharmaceuticals, Merz Therapeutics, Apurano Pharmaceuticals, Vertex

“Peripheral Neuropathic Pain Market 2034”

The Peripheral Neuropathic Pain market growth is driven by factors like increase in the prevalence of Peripheral Neuropathic Pain, investments in research and development, entry of emerging therapies during the study period 2020-2034.

The Peripheral Neuropathic Pain market report also offers comprehensive insights into the Peripheral Neuropathic Pain market size, share, Peripheral Neuropathic Pain epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Peripheral Neuropathic Pain market size growth forward.

Some of the key highlights from the Peripheral Neuropathic Pain Market Insights Report:

Several key pharmaceutical companies, including Daiichi Sankyo, Scilex Pharmaceuticals, Azurity Pharmaceuticals, Lexicon Pharmaceuticals, Merz Therapeutics, Apurano Pharmaceuticals, Vertex Pharmaceuticals, WEX Pharmaceuticals, Scilex Holding Company, and others, are developing novel products to improve the Peripheral Neuropathic Pain treatment outlook.
In November 2023, Lexicon Pharmaceuticals announced the enrollment of the first patient in the PROGRESS study, a Phase IIb, dose-ranging, randomized, double-blind, placebo-controlled, parallel-group, multicenter trial with an open-label extension, evaluating LX9211 for diabetic peripheral neuropathic pain.
In 2023, the Peripheral Neuropathic Pain (PNP) market in the 7MM was valued at approximately USD 12 billion, with projections indicating significant growth by 2034 at a notable CAGR. The United States holds the largest market share compared to EU4 (Germany, Spain, Italy, France), the UK, and Japan.
PNP arises from damage to the peripheral nervous system due to factors such as mechanical trauma, metabolic disorders, infections, neurotoxic chemicals, or tumors. Among its various causes, diabetic peripheral neuropathy (DPN) is the most common subtype in the 7MM, followed by lumbosacral radiculopathy (LSR), post-operative and post-traumatic PNP, and chemotherapy-induced peripheral neuropathy (CIPN). Postherpetic neuralgia (PHN), a complication of shingles, is the least prevalent.
Treatment options include anticonvulsants, tricyclic antidepressants, and SNRIs, alongside topical agents like capsaicin and lidocaine. Nonpharmacological approaches, such as physical therapy and TENS, complement drug therapies. Approved treatments include QUTENZA, NUCYNTA ER, HORIZANT, ZTlido, and TARLIGE.
The market is expected to expand significantly with the introduction of emerging therapies, offering novel treatment options. Key pipeline drugs include AP-325, XEOMIN, VX-548, LX9211, HALNEURON, SEMDEXA, and adezunap. Among these, LX9211 and SEMDEXA are projected to lead the market by 2034. However, adezunap faces challenges such as legal restrictions, public stigma, and quality control concerns, limiting its adoption. Meanwhile, ZTlido has captured a substantial share of the lidocaine patch market but may encounter competition from generic alternatives.
The market’s growth will primarily be driven by the development of more targeted and personalized therapies addressing both symptoms and underlying causes of PNP.
As per DelveInsight analysis, the Peripheral Neuropathic Pain market is anticipated to witness growth at a considerable CAGR

Strategise your business goals by understanding market dynamics @ Peripheral Neuropathic Pain Market Landscape

Peripheral Neuropathic Pain Overview

Peripheral neuropathies refer to disorders affecting peripheral nerve cells and fibers, arising from various underlying conditions. These nerves include cranial nerves, spinal nerve roots and ganglia, nerve trunks and branches, as well as autonomic nervous system nerves. Peripheral neuropathies are classified into different types, such as mononeuropathies (affecting a single nerve), multiple mononeuropathies or mononeuropathy multiplex (impacting two or more nerves in separate areas), and polyneuropathies (involving widespread nerve damage).

The diverse symptom presentation allows for the identification of distinct clinical phenotypes, which are crucial for guiding diagnostic evaluations. Nerve conduction studies help determine whether the neuropathy is axonal or demyelinating and assess its severity. Additional diagnostic methods, such as genetic testing, cerebrospinal fluid (CSF) analysis, nerve imaging, and nerve biopsy, may be utilized in specific cases to refine diagnosis and treatment approaches.

Do you know the treatment paradigms for different countries? Download our Peripheral Neuropathic Pain Market Sample Report

Peripheral Neuropathic Pain Epidemiology Insights

In 2023, the United States reported the highest number of Peripheral Neuropathic Pain (PNP) cases among the 7MM, totaling approximately 35.2 million.
Across the 7MM, the highest incidence of severe cases was observed in post-operative and post-traumatic PNP, whereas moderate cases were more prevalent in postherpetic neuralgia (PHN).

Peripheral Neuropathic Pain Epidemiology Segmentation

DelveInsight’s Peripheral Neuropathic Pain market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Peripheral Neuropathic Pain historical patient pools and forecasted Peripheral Neuropathic Pain patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Peripheral Neuropathic Pain Market report proffers epidemiological analysis for the study period 2020-34 in the 7MM segmented into:

Peripheral Neuropathic Pain Prevalence
Age-Specific Peripheral Neuropathic Pain Prevalence
Gender-Specific Peripheral Neuropathic Pain Prevalence
Diagnosed and Treatable Cases of Peripheral Neuropathic Pain

Visit for more @ Peripheral Neuropathic Pain Epidemiological Insights

Peripheral Neuropathic Pain Market Outlook

Pharmaceutical companies such as Scilex Holding Company, Grünenthal and Averitas Pharma, Eli Lilly and Company, Mitsubishi Tanabe Pharma Corporation, AstraZeneca, Asahi Kasei Pharma, and Veloxis Pharmaceuticals are actively advancing their lead candidates through various stages of clinical development to explore potential treatments for Peripheral Neuropathic Pain (PNP).

Among emerging therapies, LX9211 and SEMDEXA are anticipated to become market leaders, significantly shaping the PNP market across the 7MM by 2034.

In 2023, opioids dominated the U.S. PNP market, generating approximately USD 2,400 million in revenue, followed closely by NSAIDs at around USD 2,300 million.

Adezunap is expected to see limited adoption in the 7MM due to regulatory challenges, public perception issues, high-risk classification, and quality control concerns related to cannabidiol in emerging markets, all of which impact its market acceptance and manufacturing standards.

Within the EU4 and the UK, NSAIDs contributed the highest revenue in the PNP market, generating approximately USD 600 million in 2023.

Peripheral Neuropathic Pain Marketed Drugs

QUTENZA (capsaicin): Grünenthal and Averitas Pharma
ZTLIDO (lidocaine): Scilex Pharmaceuticals

Peripheral Neuropathic Pain Emerging Drugs

SEMDEXA (SP-102): Scilex Holding Company
Adezunap (AP707): Apurano Pharmaceuticals

Peripheral Neuropathic Pain Key Companies

Daiichi Sankyo, Scilex Pharmaceuticals, Azurity Pharmaceuticals, Lexicon Pharmaceuticals, Merz Therapeutics, Apurano Pharmaceuticals, Vertex Pharmaceuticals, WEX Pharmaceuticals, Scilex Holding Company, and others

For more information, visit Peripheral Neuropathic Pain Market Analysis, Patient Pool, and Emerging Therapies

Scope of the Peripheral Neuropathic Pain Market Report:

11 Years Forecast
7MM Coverage
Descriptive overview of Peripheral Neuropathic Pain, causes, signs and symptoms, diagnosis, treatment
Comprehensive insight into Peripheral Neuropathic Pain epidemiology in the 7MM
Peripheral Neuropathic Pain marketed and emerging therapies
Peripheral Neuropathic Pain companies
Peripheral Neuropathic Pain market drivers and barriers

Table of Contents:

1 Peripheral Neuropathic Pain Market Key Comprehensive Insights

2 Peripheral Neuropathic Pain Market Report Introduction

3 Competitive Intelligence Analysis for Peripheral Neuropathic Pain

4 Peripheral Neuropathic Pain Market Analysis Overview at a Glance

5 Executive Summary of Peripheral Neuropathic Pain

6 Peripheral Neuropathic Pain Epidemiology and Market Methodology

7 Peripheral Neuropathic Pain Epidemiology and Patient Population

8 Peripheral Neuropathic Pain Patient Journey

9 Peripheral Neuropathic Pain Treatment Algorithm, Peripheral Neuropathic Pain Current Treatment, and Medical Practices

10 Key Endpoints in Peripheral Neuropathic Pain Clinical Trials

11 Peripheral Neuropathic Pain Marketed Therapies

12 Peripheral Neuropathic Pain Emerging Therapies

13 Peripheral Neuropathic Pain: 7 Major Market Analysis

14 Attribute analysis

15 Access and Reimbursement Overview of Peripheral Neuropathic Pain

16 Peripheral Neuropathic Pain Market Key Opinion Leaders Reviews

18 Peripheral Neuropathic Pain Market Drivers

19 Peripheral Neuropathic Pain Market Barriers

20 SWOT Analysis

21 Disclaimer

22 DelveInsight Capabilities

23 About DelveInsight

Related Reports:

Peripheral Neuropathic Pain Epidemiology 2034

DelveInsight’s “Peripheral Neuropathic Pain – Epidemiology Forecast to 2034” report delivers an in-depth understanding of the disease, historical and forecasted Peripheral Neuropathic Pain epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Peripheral Neuropathic Pain Pipeline 2024

“Peripheral Neuropathic Pain Pipeline Insights, 2024” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Peripheral Neuropathic Pain market. A detailed picture of the Peripheral Neuropathic Pain pipeline landscape is provided, which includes the disease overview and Peripheral Neuropathic Pain treatment guidelines.

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Peripheral Neuropathic Pain Market Expected to rise, 2034 | Daiichi Sankyo, Scilex Pharmaceuticals, Azurity Pharmaceuticals, Lexicon Pharmaceuticals, Merz Therapeutics, Apurano Pharmaceuticals, Vertex

Dup15q Syndrome Market Expected to rise, 2032 | Ovid Therapeutics, Takeda, Q-State Biosciences, Radius Health, Zogenix, expected to drive market

“Dup15q Syndrome Market 2032”

The Dup15q Syndrome market growth is driven by factors like increase in the prevalence of Dup15q Syndrome, investments in research and development, entry of emerging therapies during the study period 2019-2032.

The Dup15q Syndrome market report also offers comprehensive insights into the Dup15q Syndrome market size, share, Dup15q Syndrome epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Dup15q Syndrome market size growth forward.

Some of the key highlights from the Dup15q Syndrome Market Insights Report:

According to DelveInsight, the Dup15q Syndrome Market is projected to grow at a strong rate during the forecast period (2023-2032), driven by the introduction of new therapies.
In November 2024, Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) announced Phase 1/2 data that supports the Phase 3 Aspire study for GTX-102, its experimental antisense oligonucleotide aimed at treating Angelman syndrome. This data will be showcased at the 2024 Foundation for Angelman Syndrome Therapeutics (FAST) Global Science Summit.
Key companies in the Dup15q Syndrome market, including Ovid Therapeutics, Takeda, Q-State Biosciences, Radius Health, and Zogenix, are actively contributing to its development.

Strategise your business goals by understanding market dynamics @ Dup15q Syndrome Market Landscape

Dup15q Syndrome Overview

Dup15q syndrome is a rare genetic condition caused by the duplication of part of chromosome 15, leading to various developmental challenges. It is characterized by hypotonia (low muscle tone), delays in motor skills, intellectual disability (ID), autism spectrum disorder (ASD), and epilepsy, with infantile spasms being a common type of seizure. The severity of these symptoms can vary depending on the specific genetic duplication and whether it is inherited from the mother or father.

Diagnosis of maternal dup15q syndrome is confirmed by detecting an extra copy of the Prader-Willi/Angelman critical region on chromosome 15q11.2-q13.1. Individuals with dup15q syndrome often show hypotonia in infancy, motor delays, ID, and language delays.

Currently, there is no cure for dup15q syndrome, but symptoms can be managed with treatments like antiepileptic medications, and therapies such as physical, occupational, and speech therapy. Applied behavioral analysis (ABA) therapy is also used to address social skill deficits associated with the syndrome.

Do you know the treatment paradigms for different countries? Download our Dup15q Syndrome Market Sample Report

Dup15q Syndrome Epidemiology Insights

In 2021, there were approximately 5,000 diagnosed cases of dup15q syndrome in the United States. According to DelveInsight’s projections, this number is anticipated to rise by 2032.
In the EU4 and the UK, the total number of prevalent dup15q syndrome cases was around 15,600 in 2021, with expectations for steady growth during the study period.

Dup15q Syndrome Epidemiology Segmentation

DelveInsight’s Dup15q Syndrome market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Dup15q Syndrome historical patient pools and forecasted Dup15q Syndrome patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Dup15q Syndrome Market report proffers epidemiological analysis for the study period 2019-32 in the 7MM segmented into:

Dup15q Syndrome Prevalence
Age-Specific Dup15q Syndrome Prevalence
Gender-Specific Dup15q Syndrome Prevalence
Diagnosed and Treatable Cases of Dup15q Syndrome

Visit for more @ Dup15q Syndrome Epidemiological Insights

Dup15q Syndrome Market Dynamics

The Dup15q Syndrome drug market is shaped by both driving factors and challenges. On the positive side, growing awareness and understanding of this rare genetic disorder have led to earlier diagnoses and increased demand for treatments. Additionally, advancements in precision medicine and the development of targeted therapies present opportunities to address specific symptoms, such as epilepsy and developmental delays. Collaboration between patient advocacy groups and research organizations has also accelerated progress in Dup15q syndrome research, driving innovation.

However, several obstacles hinder progress in the market. The rarity and diversity of the condition make it difficult to conduct large-scale clinical trials and create standardized treatments. Limited public awareness and delayed diagnoses can also lead to late interventions. Additionally, the high cost of specialized therapies may restrict access for some patients. Overcoming these barriers and expanding research efforts will be crucial for advancing the market and improving the lives of those with Dup15q Syndrome.

Numerous emerging therapies are under development, offering new therapeutic options with innovative mechanisms to treat Dup15q syndrome. Key companies involved in this space include Roche, Takeda, Q-State Biosciences, Ovid Therapeutics, Radius Health, Zogenix, and others.

Dup15q Syndrome Key Companies

Ovid Therapeutics
Takeda
Q-State Biosciences
Radius Health
Zogenix, and others

For more information, visit Dup15q Syndrome Market Analysis, Patient Pool, and Emerging Therapies

Scope of the Dup15q Syndrome Market Report:

11 Years Forecast
7MM Coverage
Descriptive overview of Dup15q Syndrome, causes, signs and symptoms, diagnosis, treatment
Comprehensive insight into Dup15q Syndrome epidemiology in the 7MM
Dup15q Syndrome marketed and emerging therapies
Dup15q Syndrome companies
Dup15q Syndrome market drivers and barriers

Table of Contents:

1 Dup15q Syndrome Market Key Comprehensive Insights

2 Dup15q Syndrome Market Report Introduction

3 Competitive Intelligence Analysis for Dup15q Syndrome

4 Dup15q Syndrome Market Analysis Overview at a Glance

5 Executive Summary of Dup15q Syndrome

6 Dup15q Syndrome Epidemiology and Market Methodology

7 Dup15q Syndrome Epidemiology and Patient Population

8 Dup15q Syndrome Patient Journey

9 Dup15q Syndrome Treatment Algorithm, Dup15q Syndrome Current Treatment, and Medical Practices

10 Key Endpoints in Dup15q Syndrome Clinical Trials

11 Dup15q Syndrome Marketed Therapies

12 Dup15q Syndrome Emerging Therapies

13 Dup15q Syndrome: 7 Major Market Analysis

14 Attribute analysis

15 Access and Reimbursement Overview of Dup15q Syndrome

16 Dup15q Syndrome Market Key Opinion Leaders Reviews

18 Dup15q Syndrome Market Drivers

19 Dup15q Syndrome Market Barriers

20 SWOT Analysis

21 Disclaimer

22 DelveInsight Capabilities

23 About DelveInsight

Related Reports:

Dup15q Syndrome Epidemiology 2032

DelveInsight’s “Dup15q Syndrome – Epidemiology Forecast to 2032″ report delivers an in-depth understanding of the disease, historical and forecasted Dup15q Syndrome epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Dup15q Syndrome Pipeline 2024

“Dup15q Syndrome Pipeline Insights, 2024” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Dup15q Syndrome market. A detailed picture of the Dup15q Syndrome pipeline landscape is provided, which includes the disease overview and Dup15q Syndrome treatment guidelines.

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Dup15q Syndrome Market Expected to rise, 2032 | Ovid Therapeutics, Takeda, Q-State Biosciences, Radius Health, Zogenix, expected to drive market

Tanka Brings AI Memory to Workplace Chat

Redwood City, CA – 18th Feb, 2025 – Tanka, the world’s first AI-powered messenger with long-term memory, is taking on Slack with its official launch today. Backed by Shanda Group, a global investment group that has funded 75+ VC funds and operates the Chen Institute (TCCI), a leading research institute focused on bridging human cognition and artificial intelligence, Tanka is pioneering neuroscience-inspired AI memory technology – MemGraph – which turns business conversations into actionable intelligence, redefining how organizations retain and utilize knowledge.

AI That Remembers

Learn more about Tanka: https://www.youtube.com/watch?v=gvYyySgCgb0

Conventional chat apps like Slack and Microsoft Teams create fragmented silos of conversation. On average teams waste 30% of their time searching for past information. “After years working at Meta, TikTok and my own startup, Mindverse, I saw firsthand how painful it is searching for past discussions, re-explaining things, and losing institutional knowledge. AI memory solves this problem at scale, and that’s what led to Tanka AI,” said Kisson Lin, CEO of Tanka.

“Tanka doesn’t just respond—it remembers, learns, and surfaces knowledge proactively. Whether it’s a past conversation, a critical decision, or an ongoing project update, Tanka auto-retrieves in-context memories with critical insights, follow-ups and decisions, and organizes them in one place.”

Breaking AI’s Memory Bottleneck

Long-term memory (LTM) is the missing piece in AI evolution. Traditional AI assistants rely on Retrieval-Augmented Generation (RAG), which retrieves data but lacks relational understanding and contextual reasoning.

Tanka’s long-term memory technology, MemGraph, addresses these challenges by structuring knowledge hierarchically, enabling AI to go beyond simple fact retrieval, offering deeper reasoning, contextual connections, and actionable insights. Compared to RAG, MemGraph is better at:

Hierarchical Knowledge Representation: AI structures knowledge in layers, making it easier to connect related concepts, like a well-organized library.
Ontology Learning: AI categorizes and links knowledge dynamically, like a neural network of ideas, constantly mapping and refining connections between concepts.
Temporal Awareness: AI tracks changes over time, helping it consider past trends and evolving context, similar to how a strategist assesses past trends to make informed decisions.
Multi-Resolution Retrieval: AI retrieves information at different levels of detail, zooming in on specifics or summarizing broadly as needed.
In-context and Reinforcement Learning: Tanka’s AI learns from user feedback in real time, adapting quickly without large-scale retraining.

In addition to MemGraph, Tanka also developed an industry-leading multi-agent AI framework – OMNE – to power the personalized AI assistant for every user. OMNE recently topped the GAIA benchmark for general-purpose AI assistants, outperforming models from Microsoft Research and other leading institutions.

The Future of Work Has Memory

Tanka isn’t just another SaaS tool — it replaces rigid templates with AI-driven workflows, where natural language builds and adapts processes in real-time, like 3D printing solutions instead of stacking LEGO blocks. A few key differentiations:

Personalized AI Memory for Teams: Automatically extracts actions, decisions, and insights from chats and integrated tools, ensuring institutional knowledge is preserved.
Enhanced Efficiency with Smart AI Responses: Tanka integrates with other communication tools such as Slack, Telegram, WhatsApp, Outlook and Gmail. Whether the conversation is on Tanka or one of the integrated tools, Tanka AI can generate a ‘Smart Reply’ to messages. The replies are not only context-aware, but they also have relevant information from memory, calendar, and more. Moreover, it learns from one’s language style with few-shot learning. Since its alpha pilot launch in October 2024, Tanka had already generated 35,000+ AI-generated smart replies, or 16.5 smart replies per user per month, saving its customers equivalent of 111 workdays.
AI Assistant for Every User: Every user gets an AI assistant in all chat groups, capable of summarizing conversations, retrieving key information, and scheduling tasks. “Imagine having a 24/7 work assistant who remembers everything you say. And in the future, you can even have your assistant collaborating with other colleagues’ assistants.” Kisson explained.

Finally, Tanka is built with enterprise-grade security at its core—ensuring all data is encrypted, secured, and fully compliant with industry regulations. User data is never used for AI model training, and humans remain in full control with strict data governance ensuring transparency and accountability in AI interactions.

The age of static software is over. AI has already transformed how we interact with technology—now, AI with memory is transforming how organizations think, operate, and endure. Memory is the DNA of an organization, carrying its knowledge, decisions, and vision forward. Tanka doesn’t just boost productivity; it ensures businesses evolve, adapt, and build lasting legacies. This isn’t just an upgrade—it’s a paradigm shift. AI is no longer a passive tool; it’s an active, evolving partner, making work smarter, decisions sharper, and knowledge immortal. The future belongs to organizations that remember.

About Tanka

Tanka is the world’s first messenger with AI long-term memory. Inspired by decades of neuroscience research, it is your enterprise brain that grows and evolves alongside your team. As your productivity partner, Tanka learns from your business context, past conversations and connected apps to deliver fast, precise and context-rich AI-assisted email and message replies, timely reminders, and actionable suggestions — all within your chat.

For early access, visit www.tanka.ai.

For media inquiries, please contact:

Kisson Lin, CEO of Tanka

marketing@tanka.ai

Media Contact
Company Name: Tanka, Inc.
Contact Person: Kisson Lin
Email: Send Email
Country: United States
Website: www.tanka.ai

Top Real Estate Agent in Las Vegas, NV, Celebrates Milestone of 500 Clients Served with Exceptional Expertise

Cynthia Glickman, a leading real estate agent in Las Vegas, NV, is celebrating a significant milestone — serving her 500th client. This achievement reflects her unwavering commitment to providing personalized and professional service to buyers and sellers throughout Las Vegas. With over two decades of experience, Glickman has built a reputation for guiding clients through every step of the real estate process with expertise and care.

“I am incredibly grateful to have reached this milestone,” says Glickman. “Each of my clients holds a special place in my heart, and I strive to make every experience smooth and rewarding. My focus is on providing the highest level of service, ensuring that clients feel heard, understood, and supported throughout their journey.”

The real estate market in Las Vegas is constantly evolving, with economic shifts, interest rates, and technology impacting how buyers and sellers navigate the process. As a trusted Realtor in Las Vegas, NV, Glickman stays informed on the latest trends and market dynamics, using her knowledge to adapt and guide clients in an ever-changing landscape. Her experience and analytical skills enable her to negotiate favorable terms and secure the best possible outcomes for her clients.

One of the key factors behind Glickman’s success is her dedication to communication and empathy. As a Realtor agent in Las Vegas, NV, she understands that each client’s needs are unique. Whether clients are looking for their first home, seeking investment properties, or upgrading to a larger space, Glickman tailors her approach to ensure their goals are met with precision and care.

For those looking to make a move in Las Vegas, or sell a property, Glickman’s expertise and personalized approach make her the ideal choice. Contact Cynthia Glickman, real estate listing agent in Las Vegas, NV, at https://cynthiaglickmanrealtor.com/ to start your journey today. Let Cynthia guide you every step of the way with the same dedication that has earned her the trust of over 500 clients.

Media Contact
Company Name: Cynthia Glickman | Real Estate Agent in Las Vegas, NV | Windermere Real Estate
Contact Person: Cynthia Glickman
Email: Send Email
Phone: +1 702-829-2424
Address:10845 Griffith Peak Dr
City: Las Vegas
State: Nevada 89135
Country: United States
Website: http://windermereexcellence.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Top Real Estate Agent in Las Vegas, NV, Celebrates Milestone of 500 Clients Served with Exceptional Expertise

Treatment-Resistant Depression Drugs Market 2032: EMA, PDMA, FDA Approvals, Clinical Trials, Medication, Prevalence, Incidence, NDA Approvals, Therapies, and Companies by DelveInsight

“Treatment-Resistant Depression Drugs Market”

Treatment-Resistant Depression companies working in the market are Navitor Pharmaceuticals, Supernus Pharmaceuti, Novartis, Relmada Therapeutics, Beckley Psytech, COMPASS Pathways, Axsome Therapeutics, Celon Pharma, and several others.

(Albany, USA) DelveInsight’s “Treatment-Resistant Depression Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of Treatment-Resistant Depression, historical and forecasted epidemiology as well as the Treatment-Resistant Depression market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

The Treatment-Resistant Depression market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Treatment-Resistant Depression market size from 2019 to 2032, segmented by seven major markets. The Report also covers current Treatment-Resistant Depression treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Treatment-Resistant Depression market.

Request for a Free Sample Report @ Treatment-Resistant Depression Market Forecast

Some facts of the Treatment-Resistant Depression Market Report are:

According to DelveInsight, Treatment-Resistant Depression market size is expected to grow at a decent CAGR by 2032.
The total Treatment-Resistant Depression market size in the 7MM was approximately ~USD 3,100 million in 2022 and is projected to increase during the forecast period (2023–2032).
Leading Treatment-Resistant Depression companies working in the market are Navitor Pharmaceuticals, Supernus Pharmaceuti, Novartis, Relmada Therapeutics, Beckley Psytech, COMPASS Pathways, Axsome Therapeutics, Celon Pharma, and several others.
Key Treatment-Resistant Depression Therapies expected to launch in the market are SPRAVATO (esketamine), MIJ821, COMP360 (Psilocybin), and others.
On April 2024, COMPASS Pathways announced results of a Phase III, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With Treatment-resistant Depression.
On November 2023, Navitor Pharmaceuticals announced results A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of NV-5138 in Adults With Treatment Resistant Depression

Treatment-Resistant Depression Overview

Treatment-Resistant Depression (TRD) is a severe form of depression that does not respond adequately to standard antidepressant treatments. Treatment-Resistant Depression is diagnosed when individuals fail to achieve symptom relief despite undergoing at least two different antidepressant trials at the appropriate dosage and duration. Treatment-Resistant Depression affects a significant percentage of patients with major depressive disorder (MDD), leading to prolonged distress and functional impairment.

Treatment-Resistant Depression requires a multifaceted approach, including medication adjustments, augmentation strategies, and non-pharmacological interventions. Common treatments for Treatment-Resistant Depression include switching antidepressants, combining multiple medications, or adding atypical antipsychotics. Additionally, advanced treatment options for Treatment-Resistant Depression include electroconvulsive therapy (ECT), transcranial magnetic stimulation (TMS), and ketamine-based therapies.

Treatment-Resistant Depression is influenced by various factors, such as genetic predisposition, neurochemical imbalances, and co-existing psychiatric or medical conditions. Due to the complexity of Treatment-Resistant Depression, personalized treatment plans are essential for better patient outcomes. Researchers continue to explore novel therapies for Treatment-Resistant Depression, such as psychedelic-assisted treatments and neurostimulation techniques.

Treatment-Resistant Depression significantly impacts the quality of life, making early diagnosis and tailored interventions crucial. Ongoing research and innovative therapies offer hope for individuals struggling with Treatment-Resistant Depression.

Learn more about Treatment-Resistant Depression treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ https://www.delveinsight.com/sample-request/treatment-resistant-depression-trd-market

Treatment-Resistant Depression Market

The Treatment-Resistant Depression market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Treatment-Resistant Depression market trends by analyzing the impact of current Treatment-Resistant Depression therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.

This segment gives a thorough detail of the Treatment-Resistant Depression market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Treatment-Resistant Depression market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Treatment-Resistant Depression market in 7MM is expected to witness a major change in the study period 2019-2032.

Treatment-Resistant Depression Epidemiology

The Treatment-Resistant Depression epidemiology section provides insights into the historical and current Treatment-Resistant Depression patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Treatment-Resistant Depression market report also provides the diagnosed patient pool, trends, and assumptions.

Explore more about Treatment-Resistant Depression Epidemiology @ Treatment-Resistant Depression Market Dynamics

Treatment-Resistant Depression Drugs Uptake

This section focuses on the uptake rate of the potential Treatment-Resistant Depression drugs recently launched in the Treatment-Resistant Depression market or expected to be launched in 2019-2032. The analysis covers the Treatment-Resistant Depression market uptake by drugs, patient uptake by therapies, and sales of each drug.

Treatment-Resistant Depression Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Treatment-Resistant Depression market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Treatment-Resistant Depression Pipeline Development Activities

The Treatment-Resistant Depression report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Treatment-Resistant Depression key players involved in developing targeted therapeutics.

Request for a sample report to understand more about the Treatment-Resistant Depression pipeline development activities @ https://www.delveinsight.com/sample-request/treatment-resistant-depression-trd-market

Treatment-Resistant Depression Therapeutics Assessment

Major key companies are working proactively in the Treatment-Resistant Depression Therapeutics market to develop novel therapies which will drive the Treatment-Resistant Depression treatment markets in the upcoming years are Navitor Pharmaceuticals, Supernus Pharmaceuti, Novartis, Relmada Therapeutics, Beckley Psytech, COMPASS Pathways, Axsome Therapeutics, Celon Pharma, and several others.

Learn more about the emerging Treatment-Resistant Depression therapies & key companies @ https://www.delveinsight.com/sample-request/treatment-resistant-depression-trd-market

Treatment-Resistant Depression Report Key Insights

1. Treatment-Resistant Depression Patient Population

2. Treatment-Resistant Depression Market Size and Trends

3. Key Cross Competition in the Treatment-Resistant Depression Market

4. Treatment-Resistant Depression Market Dynamics (Key Drivers and Barriers)

5. Treatment-Resistant Depression Market Opportunities

6. Treatment-Resistant Depression Therapeutic Approaches

7. Treatment-Resistant Depression Pipeline Analysis

8. Treatment-Resistant Depression Current Treatment Practices/Algorithm

9. Impact of Emerging Therapies on the Treatment-Resistant Depression Market

Table of Contents

1. Key Insights

2. Executive Summary

3. Treatment-Resistant Depression Competitive Intelligence Analysis

4. Treatment-Resistant Depression Market Overview at a Glance

5. Treatment-Resistant Depression Disease Background and Overview

6. Treatment-Resistant Depression Patient Journey

7. Treatment-Resistant Depression Epidemiology and Patient Population

8. Treatment-Resistant Depression Treatment Algorithm, Current Treatment, and Medical Practices

9. Treatment-Resistant Depression Unmet Needs

10. Key Endpoints of Treatment-Resistant Depression Treatment

11. Treatment-Resistant Depression Marketed Products

12. Treatment-Resistant Depression Emerging Therapies

13. Treatment-Resistant Depression Seven Major Market Analysis

14. Attribute Analysis

15. Treatment-Resistant Depression Market Outlook (7 major markets)

16. Treatment-Resistant Depression Access and Reimbursement Overview

17. KOL Views on the Treatment-Resistant Depression Market

18. Treatment-Resistant Depression Market Drivers

19. Treatment-Resistant Depression Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/regulatory-analysis-services

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Treatment-Resistant Depression Drugs Market 2032: EMA, PDMA, FDA Approvals, Clinical Trials, Medication, Prevalence, Incidence, NDA Approvals, Therapies, and Companies by DelveInsight